Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ampio Pharmaceuticals (NY: AMPE )

0.2902 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ampio Pharmaceuticals

< Previous 1 2 3 Next >
26 Stocks Moving in Thursday's Pre-Market Session
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) rose 35% to $1.06 in pre-market trading. Kiromic BioPharma, last month, reported changes in management and board of... 
Via Benzinga
Ampio Highlights Promising Ampion Data In Knee Osteoarthritis
Ampio Pharmaceuticals Inc (NYSE: AMPE) announced data from the modified Intent-to-Treat (mITT) population in the AP-013 Phase 3 trial of Ampion in severe osteoarthritis of... 
Via Benzinga
Ampio To Test Inhaled COVID-19 Treatment In India
The Drugs Controller General of India (DCGI) of the Central Drugs Standard Control Organization (CDSCO) has approved Phase 2 COVID-19 trial of Ampio... 
Via Benzinga
Exposures COVID-19
Why Ampio Pharmaceuticals Stock Is Trading Higher Today
Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading higher Wednesday after the company announced top-line results from the AP-013 Phase III study of Ampion in... 
Via Benzinga
EXCLUSIVE: Ampio's Ampion Shows Benefit In Late-Stage Knee Osteoarthritis Study
Ampio Pharmaceuticals Inc (NYSE: AMPE) has reported top-line results from the AP-013 Phase 3 trial evaluating the Company's intra-articular (IA) injection of Ampion in... 
Via Benzinga
Earnings Scheduled For May 5, 2021
Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter. • EyePoint Pharmaceuticals (NASDAQ:EYPT... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Here's Why Ampio Pharmaceuticals Stock Is Surging Today
A positive second-quarter earnings report and anticipation of further details to be discussed this afternoon helped this beaten-down biotech stock recover some previous losses. 
Via The Motley Fool
Exposures COVID-19
Ampio To Present At October Scientific Conference Evidence Of Ampion's Role In Treating Lupus Nephritis, COVID-19
Ampio Pharmaceuticals, Inc. (NYSE: AMPE), a biopharma developing immunotherapies for inflammatory conditions, is set to present data on lead drug Ampio at a scientific conference... 
Via Benzinga
Ampio's Phase 2 Study Of Inhaled Ampion In COVID-19 Patients Gets Underway
Ampio Pharmaceuticals, Inc. (NYSE: AMPE) announced an update to its COVID-19 program that is evaluating its lead asset Ampion. What Happened: Colorado-based Ampio announced the... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Ampio Stock Jumps On Enrollment Expansion Of Mid-Stage COVID-19 Trial To India With Inhaled Ampion
Ampio Pharmaceuticals Inc (NYSE: AMPE) has received regulatory approval to expand enrollment of its AP-019 Phase 2 study to India, assessing inhaled Ampion to... 
Via Benzinga
Exposures COVID-19
EXCLUSIVE: Ampio Pharmaceuticals Approved For Clinical Study Of Lead Drug In Long-Term Respiratory COVID-19 Symptoms
Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE), a biopharma developing immunology-based therapies for inflammatory diseases, announced Monday it has received approval to initiate a... 
Via Benzinga
Exposures COVID-19
Ampio Pharma's Inhaled COVID-19 Treatment Shows 78% Improvement In All-Cause Mortality
Ampio Pharmaceuticals Inc (NYSE: AMPE) revealed positive results from its AP-014 Phase 1 trial utilizing inhaled Ampion in treating respiratory distress in... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.